Microbial proteins, membranes, and nucleic acids

Microbial proteins, membranes, and nucleic acids constitute the essential machinery and structural framework of pathogens, serving as the primary focus for antimicrobial drug development (StatPearls, 2023) [1]. Proteins, including metabolic enzymes and ribosomes, are targeted to disrupt vital biochemical pathways and protein translation, while nucleic acids like DNA and RNA are targeted to prevent genetic replication and expression (Nature Reviews Microbiology, 2013) [2]. Cell membranes and walls provide structural stability and protection; their disruption leads to the loss of cellular homeostasis and eventual lysis (NIH, 2015) [3]. The therapeutic utility of targeting these components depends on achieving selective toxicity, where the drug preferentially affects the microbe over the human host by exploiting unique biochemical differences (StatPearls, 2023) [1]. However, the clinical efficacy of drugs hitting these targets is increasingly threatened by the emergence of resistance mechanisms, such as target modification or bypass (Nature Reviews Microbiology, 2013) [2]. Understanding these interactions is critical for the design of next-generation anti-infectives that can overcome existing resistance patterns (NIH, 2015) [3].

Other names

Microbial cellular componentsPathogen targetsBacterial, viral, and fungal targets

Antimicrobial agents exert their effects through several primary mechanisms: inhibition of cell wall synthesis (e.g., beta-lactams), disruption of cell membrane integrity (e.g., polymyxins), inhibition of protein synthesis by targeting ribosomal subunits (e.g., macrolides, aminoglycosides), and interference with nucleic acid synthesis or function (e.g., fluoroquinolones, rifamycins) (StatPearls, 2023) [1].